Search - tctmd.com

Displaying 1 - 20 of 31

Sort: Relevancy | Date

Short DAPT All That’s Needed With Contemporary DES: HOST-IDEA at 3 Years

News Conference News EuroPCR 2025

Short DAPT All That’s Needed With Contemporary DES: HOST-IDEA at 3 Years

Yael L. Maxwell

June 02, 2025

Short DAPT Safe in ACS With No Ischemic Penalty: 4D-ACS

News Conference News EuroPCR 2025

Short DAPT Safe in ACS With No Ischemic Penalty: 4D-ACS

May 30, 2025

Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI

News Conference News EuroPCR 2025

Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI

Michael O'Riordan

May 20, 2025

Solid 2-Year Data With ‘Unlocking’ Coronary Stent: BIOADAPTOR RCT

News Conference News EuroPCR 2024

Solid 2-Year Data With ‘Unlocking’ Coronary Stent: BIOADAPTOR RCT

Michael O'Riordan

May 28, 2024

PCI for Multivessel Disease More Cost-effective Than CABG at 3 Years: FAME 3

News Conference News EuroPCR 2024

PCI for Multivessel Disease More Cost-effective Than CABG at 3 Years: FAME 3

Yael L. Maxwell

May 17, 2024

One-month DAPT followed by 5-month Ti - cagrelor monotherapy in acute coronary syndromes with DCB - results from REC-CAGEFREE II

Presentation EuroPCR 2024

One-month DAPT followed by 5-month Ti - cagrelor monotherapy in acute coronary syndromes with DCB - results from REC-CAGEFREE II

Presenter: Ling Tao

May 15, 2024

Is coronary artery bypass surgery cost-effective compared with contemporary PCI? A FAME 3 analysis

Presentation EuroPCR 2024

Is coronary artery bypass surgery cost-effective compared with contemporary PCI? A FAME 3 analysis

Presenter: Frederik Zimmermann

May 15, 2024

Stepwise DAPT De-escalation Shows Promise in DCB-Only PCI for ACS

News Conference News EuroPCR 2024

Stepwise DAPT De-escalation Shows Promise in DCB-Only PCI for ACS

Yael L. Maxwell

May 15, 2024

Methodological Insight: REC-CAGEFREE II Trial

Presentation EuroPCR 2024

Methodological Insight: REC-CAGEFREE II Trial

Presenter: Robert Byrne

May 14, 2024

‘Fascinating’ Unlocking Coronary Stent Prompts Cautious Praise

News Conference News EuroPCR 2023

‘Fascinating’ Unlocking Coronary Stent Prompts Cautious Praise

Michael O'Riordan

May 18, 2023

Imaging in PCI for Patients at High Bleeding Risk: Data Point to Possibilities

News Conference News EuroPCR 2022

Imaging in PCI for Patients at High Bleeding Risk: Data Point to Possibilities

May 25, 2022

Long-term Outcomes With PCI and CABG: More Analyses to Stir the Pot

News Conference News EuroPCR 2022

Long-term Outcomes With PCI and CABG: More Analyses to Stir the Pot

Michael O'Riordan

May 23, 2022

Ultrathin Orsiro Performs Well in All-Comers, Interim CASTLE Data Indicate

News Conference News EuroPCR 2021

Ultrathin Orsiro Performs Well in All-Comers, Interim CASTLE Data Indicate

May 24, 2021

Transradial PCI Bests Femoral Access in Complex Cases: COLOR

News Conference News EuroPCR 2021

Transradial PCI Bests Femoral Access in Complex Cases: COLOR

Michael O'Riordan

May 21, 2021

Provisional Stenting Noninferior to Planned Two-Stent Strategy for Left Main Disease: EBC MAIN

News Conference News EuroPCR 2021

Provisional Stenting Noninferior to Planned Two-Stent Strategy for Left Main Disease: EBC MAIN

May 21, 2021

The Skinny on Ultrathin DES: Meta-analysis Shows Some Long-term Advantages

News Conference News EuroPCR 2021

The Skinny on Ultrathin DES: Meta-analysis Shows Some Long-term Advantages

May 19, 2021

Tirofiban Provides Better Platelet Inhibition Than Cangrelor in STEMI Patients

News Conference News EuroPCR 2020

Tirofiban Provides Better Platelet Inhibition Than Cangrelor in STEMI Patients

Michael O'Riordan

June 30, 2020

DynamX Bioadaptor Provides Promising Preliminary Results for De Novo Coronary Lesions

News Conference News EuroPCR 2020

DynamX Bioadaptor Provides Promising Preliminary Results for De Novo Coronary Lesions

June 30, 2020

Daring to Dream: New BRS Data Hint at Low MACE Rates at 2 and 3 Years

News Conference News EuroPCR 2019

Daring to Dream: New BRS Data Hint at Low MACE Rates at 2 and 3 Years

Michael O'Riordan

May 27, 2019

Firehawk Stent Still Holds Up Well to Xience at 2 Years: TARGET All Comers

News Conference News EuroPCR 2019

Firehawk Stent Still Holds Up Well to Xience at 2 Years: TARGET All Comers

May 23, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.